Bit.bio finally details cell therapy pipeline for regenerative treatment, with initial focus on liver
Bit.bio has lifted the curtain on its early pipeline of regenerative medicine candidates made using its cell programming technology, which is intended to deterministically transform stem cells into mature cells.
The UK-based company’s lead cell therapy program, bbHEP01, comprises encapsulated hepatocyte-like cells made using its opti-ox technology. Bit.bio had previously expressed ambitions to move into cell therapy R&D using opti-ox but had not unveiled the specifics of its pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.